Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Atara Biotherapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 33 | 36 | +3 |
| Shares | 2.56M | 4.47M | +1.90M (+74.2%) |
| Value | $12.1M | $51.3M | +$39.2M (+323.0%) |
New holders (4)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 15,303 | $175.7K | 0.00% |
| Citadel Advisors LLC | 10,159 | $116.6K | 0.00% |
| Caitong International Asset Management Co., Ltd | 311 | $3.57K | 0.00% |
| Barclays PLC | 304 | $3.49K | 0.00% |
Sold out (1)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Rhumbline Advisers | 175 | $827 |